CA2882947A1 — Crystalline form of a reverse transcriptase inhibitor
Assigned to Merck Sharp and Dohme LLC · Expires 2014-04-03 · 12y expired
What this patent protects
The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type- 1 (HIV -I) and type-2 (HIV -2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individua…
USPTO Abstract
The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type- 1 (HIV -I) and type-2 (HIV -2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[( 4-methyl-5 -oxo-4,5 -dihydro-1H -1,2, 4-triazol-3 -yl)methyl]-2-oxo-4-( trifluoromethy 1 )-1,2-dihydropyridin-3 -yl) oxy )benzonitrile used in the treatment HIV infection and AIDS.
Drugs covered by this patent
- Pifeltro (DORAVIRINE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.